Siemens Fonds Invest GmbH Has $1.13 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Siemens Fonds Invest GmbH lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 54.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 15,242 shares of the medical research company's stock after selling 18,581 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Edwards Lifesciences were worth $1,128,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of EW. Prosperity Consulting Group LLC increased its position in Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after acquiring an additional 134 shares during the period. Abacus Planning Group Inc. grew its position in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after purchasing an additional 140 shares during the last quarter. Bowman & Co S.C. increased its holdings in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after purchasing an additional 148 shares during the period. Moors & Cabot Inc. raised its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock valued at $4,041,000 after buying an additional 152 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Edwards Lifesciences by 3.1% in the fourth quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock valued at $383,000 after buying an additional 156 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.09 on Thursday, hitting $75.02. 1,342,407 shares of the company were exchanged, compared to its average volume of 4,662,584. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The firm has a 50 day moving average of $72.60 and a two-hundred day moving average of $71.93. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $44.00 billion, a P/E ratio of 10.76, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.66 earnings per share. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the completion of the sale, the chief financial officer now owns 41,098 shares in the company, valued at $3,057,691.20. The trade was a 21.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,192 shares of company stock valued at $4,709,454. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on EW shares. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Finally, Piper Sandler raised their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and an average target price of $79.60.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.